Petefészekrák: vizsgálatok itt: Hollandia
32 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Where
- Amsterdam, Groningen, Nijmegen
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500 - 1. fázisTaking peopleA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Where
- Amsterdam, Maastricht, Nijmegen, Utrecht
- Életkor
- 18 év and over
- People
- 340 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00 - 3. fázisTaking peopleA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Groningen, Rotterdam
- Életkor
- 18 év and over
- People
- 1630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00 - 3. fázisTaking peopleStudy to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Where
- Amsterdam, Groningen
- Életkor
- 18 év and over
- People
- 688 worldwide
- Run by
- Genmab
See details and how to joinNCT07564141 · EU 2025-524202-15-00 - 3. fázisTaking peopleA Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Where
- Amsterdam, Nijmegen
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT06072781 · EU 2023-508204-38-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Amsterdam, Groningen, Leiden, Maastricht, Nijmegen
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Amsterdam, Groningen, Nijmegen, Rotterdam, Utrecht
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - No phaseNot yet taking people in HollandiaAI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant Before Surgery
- Where
- Amsterdam, Breda, Eindhoven, Leiden, Maastricht
- Életkor
- 18 év and over
- People
- 1300 worldwide
- Run by
- Catharina Ziekenhuis Eindhoven
See details and how to joinNCT07883551 - 1. fázisNot yet taking people in HollandiaAn open-label phase 1 dose-escalation study to evaluate safety, tolerability, pharmacokinetics, and exploratory assessments of PACAB-002 in patients with ovarian cancer with peritoneal spread
- Where
- Rotterdam
- Életkor
- 18 év and over
- People
- 21
- Run by
- Nadeno Nanoscience AS
See details and how to join2026-527184-15-00 · EU 2026-527184-15-00 - 3. fázisTaking peopleStudy to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Where
- Amsterdam, Groningen, Nijmegen, Rotterdam, Utrecht
- Életkor
- 18 év and over
- People
- 466 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07214779 · EU 2025-522748-42-00 - 1/2. fázisTaking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - 1/2. fázisTaking peopleExploiting the synergistic effect of PARP inhibition with cisplatin and hyperthermia during interval cytoreductive surgery and HIPEC in ovarian cancer: The PROOV study - A Phase I/II clinical trial
- Where
- Amsterdam, Utrecht
- Életkor
- 18 év and over
- People
- 55
- Run by
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
See details and how to join2024-519170-39-00 · EU 2024-519170-39-00 - 1/2. fázisTaking peopleStudy of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Where
- Groningen, Nijmegen, Rotterdam
- Életkor
- 18 év and over
- People
- 890 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03564340 · EU 2024-510783-23-00 - 1/2. fázisTaking peopleStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 534 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06128551 - 2. fázisTaking people[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- Where
- Groningen, Nijmegen
- Életkor
- 18 év to 79 év
- People
- 71 worldwide
- Run by
- Blue Earth Diagnostics
See details and how to joinNCT07702292 · EU 2025-521983-36-00 - 3. fázisTaking peopleMinimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 580 worldwide
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT04575935 - No phaseTaking peopleIrreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 27
- Run by
- Amsterdam UMC, location VUmc
See details and how to joinNCT07782164 - 3. fázisTaking peopleUtility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
- Where
- Amsterdam, Leiden, Nijmegen, Rotterdam
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- ARCAGY/ GINECO GROUP
See details and how to joinNCT06476184 - 2. fázisTaking peopleA Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Where
- Rotterdam
- Életkor
- 8 év and over
- People
- 254 worldwide
- Run by
- Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00 - 1/2. fázisTaking peopleFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Where
- Amsterdam, Rotterdam
- Életkor
- 18 év and over
- People
- 880 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00 - 2/3. fázisTaking peopleStudy to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
- Where
- Nieuwegein
- Életkor
- 18 év and over
- People
- 175 worldwide
- Run by
- GE Healthcare
See details and how to joinNCT07219238 · EU 2024-519384-18-00 - 2. fázisTaking peopleAbemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
- Where
- Groningen, Rotterdam, Utrecht
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- Universitaire Ziekenhuizen KU Leuven
See details and how to joinNCT05872204 · EU 2023-503533-21-00 - No phaseTaking peopleTUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
- Where
- Amsterdam, Breda, Eindhoven, Enschede, Groningen, Leeuwarden, Leiden, Maastricht, Nijmegen, Rotterdam, Tilburg, Utrecht, Veldhoven, Zwolle
- Életkor
- 25 év to 50 év
- People
- 3000 worldwide
- Run by
- University Medical Center Nijmegen
See details and how to joinNCT04294927 - 1/2. fázisTaking peopleThe PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer
- Where
- Amsterdam
- Életkor
- 18 év to 100 év
- People
- 55
- Run by
- The Netherlands Cancer Institute
See details and how to joinNCT07460180 - No phaseTaking peopleDetermining Prognostic Immune Markers in Patients With Ovarian Cancer
- Where
- Leiden
- Életkor
- 18 év and over
- People
- 300
- Run by
- Leiden University Medical Center
See details and how to joinNCT03862677